Ampio Pharmaceuticals (DB:APH) - Aandelenkoers, Nieuws & Analyse

APH Overzicht aandelen

A biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. Meer informatie

APH fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

De winst is de afgelopen 5 jaar met 28.9% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( €2M )

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandelen zijn zeer illiquide

+ 2 meer risico's

Ampio Pharmaceuticals, Inc. Concurrenten

Biofrontera

XTRA:B8FK

€16.3m

SynBiotic

DUSE:SBX

€27.9m

Cantourage Group

XTRA:HIGH

€57.6m

Redx Pharma

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Ampio Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$3.62
52 Week Hoogtepunt	US$7.40
52 Week Laag	US$2.48
Bèta	2.35
11 maand verandering	0%
3 maanden verandering	7.10%
1 Jaar Verandering	n/a
33 jaar verandering	-81.53%
5 jaar verandering	-49.58%
Verandering sinds IPO	-94.09%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	APH	DE Pharmaceuticals	DE Markt
7D	0%	1.6%	1.1%
1Y	n/a	-19.0%	7.2%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe APH presteerde ten opzichte van de German Pharmaceuticals.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe APH presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is APH's price volatile compared to industry and market?
APH volatility
APH Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: APH heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van APH in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	5	Mike Martino	ampiopharma.com

Ampio Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Ampio Pharmaceuticals zich tot de beurswaarde?
APH fundamentele statistieken
Marktkapitalisatie	€1.47m
Inkomsten(TTM)	-€8.17m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.2x

Koers/Winstverhouding

Is APH overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
APH resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$8.80m
Inkomsten	-US$8.80m

Laatst gerapporteerde inkomsten

Sep 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-10.57
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde APH op de lange termijn?

Bekijk historische prestaties en vergelijking

APH Overzicht aandelen

Risicoanalyse

Ampio Pharmaceuticals, Inc. Concurrenten

XTRA:B8FK

€16.3m

DUSE:SBX

€27.9m

XTRA:HIGH

€57.6m

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Recent updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Glancy Prongay & Murray LLP Files A Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Robbins LLP Files A Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Ampio Provides Regulatory Update

Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis for Ampion Targeting Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Ampio Pharmaceuticals, Inc. Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial

Ampio Pharmaceuticals, Inc. Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

Ampio Pharmaceuticals Reveals Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals, Inc. Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

Ampio Pharmaceuticals, Inc. Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals Provides Update on Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of Covid-19 Patients

Ampio Pharmaceuticals, Inc. Receives Feedback from the FDA on Ampio’s Proposed Modifications to the Special Protocol Asssessment for Ampion Treatment of Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals, Inc. Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals, Inc. Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

New 90-day high: €0.98

Ampio Pharmaceuticals, Inc. Announces the AP-014 Phase I Inhaled Ampion™ Clinical Study In COVID-19 Patients

Ampio Pharmaceuticals, Inc. Announces its Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Begins Phase 1 Clinical Trial of Inhaled Ampion for Covid-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Ampio Pharmaceuticals, Inc. Announces the Receipt of an Investigational New Drug from the U.S. Food and Drug Administration

New 90-day high - €0.69